Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• icotec Receives CMS Approval for New Technology Add-On Payment (NTAP) for CMORE® CT System: Reported by OrthoSpineNews, the Centers for Medicare & Medicaid Services (CMS) granted NTAP status effective October 1, 2026, for icotec's radiolucent BlackArmor® Carbon/PEEK cervicothoracic spinal stabilization system, unlocking supplemental hospital reimbursement for complex oncology and infection reconstructions.
• Stryker Announces Leadership Succession as Spencer Stiles Appointed CEO and Kevin Lobo Transitions to Executive Chair: Detailed by Orthopedics This Week, Stryker initiated a planned executive transition effective January 1, 2027, naming President and COO Spencer Stiles as Chief Executive Officer while Kevin Lobo transitions to Executive Chair after a transformative 14-year tenure marked by tripling revenue to over $26 billion.
• CMS Announces Nationwide Expansion of Comprehensive Care for Joint Replacement Model (CJR-X) Beginning 2028: Reported by Healio Orthopedics, CMS finalized the nationwide rollout of the mandatory CJR-X episode payment model starting January 1, 2028, expanding bundled episode accountability beyond hips and knees to include total ankle replacements through 90 days post-discharge.
• Carlsmed corra® Cervical Plating System Cleared: Carlsmed, Inc. secured FDA 510(k) clearance (K262149) for the corra® cervical plating system, expanding its personalized spine surgery portfolio with rigid anterior cervical fixation.
• MedShape DynaNail Helix® Fixation System Cleared: MedShape, Inc. received FDA 510(k) clearance (K260995) for the DynaNail Helix® Fixation System, indicated for bone fracture fixation and joint arthrodesis in foot and ankle reconstruction.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Orthobiologics

icotec — icotec Receives CMS Approval for New Technology Add-On Payment (NTAP) for CMORE® CT System

• Summary: The Centers for Medicare & Medicaid Services (CMS) approved a New Technology Add-On Payment (NTAP) for icotec's CMORE® CT (Cervicothoracic) spine implant system, effective October 1, 2026. Made entirely of icotec's proprietary BlackArmor® Carbon/PEEK radiolucent material, the nonmetallic system provides posterior stabilization for cervicothoracic pathologies and is the only FDA-approved system indicated for spinal infection.
• Key Details:
  • Device/System Name: CMORE® CT Cervicothoracic Spine System featuring BlackArmor® Carbon/PEEK
  • Status: CMS New Technology Add-On Payment (NTAP) Approval (Effective October 1, 2026)
  • Clinical Significance: Eliminates metallic imaging artifacts on X-ray, CT, and MRI to dramatically improve postoperative tumor surveillance, radiation therapy planning, and spine infection monitoring; the NTAP designation provides additional reimbursement for eligible inpatient Medicare procedures, reducing adoption barriers for acute-care hospitals.
• Original Source: OrthoSpineNews

Corporate, M&A & Regulatory

Stryker Corporation — Stryker Announces Planned Leadership Succession: Spencer Stiles Appointed CEO, Kevin Lobo Transitioning to Executive Chair

• Summary: Stryker announced that as part of a planned leadership succession process, Kevin Lobo will transition to Executive Chair of the Board of Directors effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer, will succeed Lobo as Chief Executive Officer and join the company's Board of Directors. Under Lobo's 14-year leadership, Stryker completed over 60 acquisitions, including Mako surgical robotics, growing revenue from $8.7 billion to more than $26 billion in 2026.
• Key Details:
  • Device/System Name: Corporate Executive Leadership Transition
  • Status: Planned Executive Leadership Succession (Effective January 1, 2027)
  • Clinical Significance: Ensures organizational continuity and strategic momentum for the global orthopaedic device leader across its core joint replacement, robotics, spine, and trauma divisions under Stiles' veteran operational leadership.
• Original Source: Orthopedics This Week

Corporate, M&A & Regulatory

Centers for Medicare & Medicaid Services (CMS) — CMS Announces Nationwide Expansion of Comprehensive Care for Joint Replacement (CJR-X) Model Beginning 2028

• Summary: The Centers for Medicare & Medicaid Services (CMS) finalized the nationwide expansion of the Comprehensive Care for Joint Replacement Expanded (CJR-X) model to commence on January 1, 2028, as part of the FY 2027 IPPS final rule. The mandatory episode-based payment model holds acute care hospitals financially accountable for spending and quality across hip, knee, and newly added ankle replacement episodes through 90 days post-discharge.
• Key Details:
  • Device/System Name: Comprehensive Care for Joint Replacement Expanded (CJR-X) Model
  • Status: Federal Regulatory Policy Final Rule (Effective January 1, 2028)
  • Clinical Significance: Expands mandatory bundled-payment accountability across all US hospital markets and incorporates total ankle arthroplasty for the first time, incentivizing surgical care standardization, reduced post-acute institutional utilization, and tighter coordination across the 90-day recovery continuum.
• Original Source: Healio Orthopedics

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.